drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00615 | DB00675 | 690 | 888 | [
"DDInter1589",
"DDInter1744"
] | Rifabutin | Tamoxifen | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
690,
24,
888
]
],
[
[
690,
6,
8374
],
[
8374,
45,
888
]
],
[
[
690,
18,
2183
],
[
2183,
57,
888
]
],
[
[
690,
21,
28709
],
[
28709,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tamoxifen (Compound)
Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Tamoxifen (Compound)
Rifabutin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Tamoxifen (... |
DB00218 | DB11837 | 1,176 | 1,297 | [
"DDInter1247",
"DDInter1351"
] | Moxifloxacin | Osilodrostat | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1176,
25,
1297
]
],
[
[
1176,
23,
112
],
[
112,
23,
1297
]
],
[
[
1176,
25,
401
],
[
401,
24,
1297
]
],
[
[
1176,
24,
657
],
[
657,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Moxifloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethazin... |
DB06317 | DB08870 | 1,626 | 850 | [
"DDInter630",
"DDInter228"
] | Elotuzumab | Brentuximab vedotin | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1626,
24,
850
]
],
[
[
1626,
24,
788
],
[
788,
24,
850
]
],
[
[
1626,
63,
671
],
[
671,
24,
850
]
],
[
[
1626,
24,
496
],
[
496,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvasta... |
DB00227 | DB11730 | 1,463 | 351 | [
"DDInter1098",
"DDInter1588"
] | Lovastatin | Ribociclib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1463,
24,
351
]
],
[
[
1463,
24,
466
],
[
466,
62,
351
]
],
[
[
1463,
24,
112
],
[
112,
23,
351
]
],
[
[
1463,
24,
310
],
[
310,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and M... |
DB00457 | DB00486 | 1,205 | 1,614 | [
"DDInter1511",
"DDInter1253"
] | Prazosin | Nabilone | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1205,
24,
1614
]
],
[
[
1205,
24,
530
],
[
530,
1,
1614
]
],
[
[
1205,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1205,
63,
999
],
[
999,... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"D... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Prazosin (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Prazosin may cause a moderat... |
DB00213 | DB04908 | 837 | 1,671 | [
"DDInter1388",
"DDInter741"
] | Pantoprazole | Flibanserin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
837,
24,
1671
]
],
[
[
837,
62,
168
],
[
168,
23,
1671
]
],
[
[
837,
24,
98
],
[
98,
63,
1671
]
],
[
[
837,
1,
1215
],
[
1215,
2... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[... | Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatre... |
DB01182 | DB11581 | 371 | 1,456 | [
"DDInter1534",
"DDInter1926"
] | Propafenone | Venetoclax | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
371,
25,
1456
]
],
[
[
371,
24,
259
],
[
259,
24,
1456
]
],
[
[
371,
25,
982
],
[
982,
63,
1456
]
],
[
[
371,
23,
466
],
[
466,
... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonace... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Propafenone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may caus... |
DB05316 | DB09073 | 749 | 951 | [
"DDInter1467",
"DDInter1379"
] | Pimavanserin | Palbociclib | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
749,
24,
951
]
],
[
[
749,
24,
1476
],
[
1476,
63,
951
]
],
[
[
749,
63,
600
],
[
600,
24,
951
]
],
[
[
749,
24,
578
],
[
578,
2... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and ... |
DB06636 | DB11967 | 1,623 | 710 | [
"DDInter980",
"DDInter210"
] | Isavuconazonium | Binimetinib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1623,
24,
710
]
],
[
[
1623,
24,
1593
],
[
1593,
24,
710
]
],
[
[
1623,
63,
1557
],
[
1557,
24,
710
]
],
[
[
1623,
25,
1406
],
[
1406,... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Astemizole... |
DB00377 | DB11915 | 1,494 | 1,293 | [
"DDInter1382",
"DDInter1909"
] | Palonosetron | Valbenazine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1494,
24,
1293
]
],
[
[
1494,
23,
112
],
[
112,
23,
1293
]
],
[
[
1494,
63,
521
],
[
521,
24,
1293
]
],
[
[
1494,
24,
401
],
[
401,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and ... |
DB00072 | DB00095 | 550 | 66 | [
"DDInter1846",
"DDInter623"
] | Trastuzumab | Efalizumab | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Moderate | 1 | [
[
[
550,
24,
66
]
],
[
[
550,
24,
151
],
[
151,
63,
66
]
],
[
[
550,
25,
375
],
[
375,
63,
66
]
],
[
[
550,
64,
581
],
[
581,
24,
... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/Calif... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerba... |
DB00414 | DB00790 | 590 | 664 | [
"DDInter16",
"DDInter1431"
] | Acetohexamide | Perindopril | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Moderate | 1 | [
[
[
590,
24,
664
]
],
[
[
590,
24,
1638
],
[
1638,
1,
664
]
],
[
[
590,
24,
954
],
[
954,
40,
664
]
],
[
[
590,
24,
460
],
[
460,
62... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (... |
DB00652 | DB06691 | 234 | 849 | [
"DDInter1421",
"DDInter1155"
] | Pentazocine | Mepyramine | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
234,
24,
849
]
],
[
[
234,
63,
1594
],
[
1594,
24,
849
]
],
[
[
234,
24,
272
],
[
272,
24,
849
]
],
[
[
234,
24,
412
],
[
412,
6... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB09073 | DB14881 | 951 | 180 | [
"DDInter1379",
"DDInter1329"
] | Palbociclib | Oliceridine | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
951,
24,
180
]
],
[
[
951,
63,
1094
],
[
1094,
24,
180
]
],
[
[
951,
24,
124
],
[
124,
24,
180
]
],
[
[
951,
64,
375
],
[
375,
2... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Gl... |
DB00694 | DB11915 | 51 | 1,293 | [
"DDInter485",
"DDInter1909"
] | Daunorubicin | Valbenazine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
51,
24,
1293
]
],
[
[
51,
23,
112
],
[
112,
23,
1293
]
],
[
[
51,
63,
521
],
[
521,
24,
1293
]
],
[
[
51,
24,
401
],
[
401,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and ... |
DB00214 | DB08882 | 1,028 | 1,281 | [
"DDInter1836",
"DDInter1070"
] | Torasemide | Linagliptin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1028,
24,
1281
]
],
[
[
1028,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1028,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
1028,
24,
251
],
[
25... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Torasemide (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Torasemide may cause a moderate interact... |
DB00514 | DB09068 | 506 | 1,427 | [
"DDInter527",
"DDInter1948"
] | Dextromethorphan | Vortioxetine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Major | 2 | [
[
[
506,
25,
1427
]
],
[
[
506,
63,
1018
],
[
1018,
24,
1427
]
],
[
[
506,
24,
1311
],
[
1311,
24,
1427
]
],
[
[
506,
24,
283
],
[
283,
... | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Metoc... |
DB00196 | DB01263 | 600 | 859 | [
"DDInter743",
"DDInter1494"
] | Fluconazole | Posaconazole | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
600,
24,
859
]
],
[
[
600,
6,
4973
],
[
4973,
45,
859
]
],
[
[
600,
54,
19182
],
[
19182,
15,
859
]
],
[
[
600,
21,
28762
],
[
28762,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Fluconazole (Compound) is included by Azoles (Pharmacologic Class) and Azoles (Pharmacologic Class) includes Posaconazole (Compound)
Fluconazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by... |
DB11703 | DB12364 | 405 | 1,421 | [
"DDInter9",
"DDInter200"
] | Acalabrutinib | Betrixaban | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
405,
25,
1421
]
],
[
[
405,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
405,
63,
992
],
[
992,
24,
1421
]
],
[
[
405,
24,
1017
],
[
1017,
... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
... | Acalabrutinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ginger and Ginger may cause a ... |
DB00637 | DB01059 | 1,557 | 956 | [
"DDInter128",
"DDInter1313"
] | Astemizole | Norfloxacin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
1557,
24,
956
]
],
[
[
1557,
24,
872
],
[
872,
40,
956
]
],
[
[
1557,
64,
1176
],
[
1176,
1,
956
]
],
[
[
1557,
24,
1539
],
[
1539,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Astemizole may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Astem... |
DB01112 | DB06723 | 665 | 115 | [
"DDInter335",
"DDInter58"
] | Cefuroxime | Aluminum hydroxide | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
665,
24,
115
]
],
[
[
665,
21,
28882
],
[
28882,
60,
115
]
],
[
[
665,
63,
1194
],
[
1194,
23,
115
]
],
[
[
665,
40,
1462
],
[
1462,
... | [
[
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Cefuroxime",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature in... | Cefuroxime (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit ... |
DB00067 | DB11986 | 317 | 484 | [
"DDInter1921",
"DDInter648"
] | Vasopressin | Entrectinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
317,
24,
484
]
],
[
[
317,
23,
112
],
[
112,
23,
484
]
],
[
[
317,
24,
774
],
[
774,
24,
484
]
],
[
[
317,
24,
1619
],
[
1619,
6... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and De... |
DB00382 | DB00468 | 62 | 1,424 | [
"DDInter1734",
"DDInter1557"
] | Tacrine | Quinine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
62,
24,
1424
]
],
[
[
62,
24,
112
],
[
112,
62,
1424
]
],
[
[
62,
24,
36
],
[
36,
63,
1424
]
],
[
[
62,
63,
1031
],
[
1031,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"M... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may ... |
DB00434 | DB09061 | 13 | 1,627 | [
"DDInter459",
"DDInter284"
] | Cyproheptadine | Cannabidiol | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
13,
24,
1627
]
],
[
[
13,
63,
1594
],
[
1594,
24,
1627
]
],
[
[
13,
24,
662
],
[
662,
24,
1627
]
],
[
[
13,
24,
407
],
[
407,
63... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamin... |
DB00308 | DB00816 | 347 | 1,674 | [
"DDInter901",
"DDInter1346"
] | Ibutilide | Orciprenaline | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
347,
25,
1674
]
],
[
[
347,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
347,
64,
618
],
[
618,
24,
1674
]
],
[
[
347,
25,
484
],
[
484,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Com... | Ibutilide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Ibutilide may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Ibutilide m... |
DB00357 | DB05676 | 1,051 | 1,513 | [
"DDInter71",
"DDInter111"
] | Aminoglutethimide | Apremilast | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
1051,
24,
1513
]
],
[
[
1051,
24,
307
],
[
307,
23,
1513
]
],
[
[
1051,
24,
1155
],
[
1155,
63,
1513
]
],
[
[
1051,
62,
1101
],
[
1101... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib a... |
DB00242 | DB11952 | 1,064 | 800 | [
"DDInter392",
"DDInter612"
] | Cladribine | Duvelisib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1064,
25,
800
]
],
[
[
1064,
24,
466
],
[
466,
62,
800
]
],
[
[
1064,
25,
310
],
[
310,
24,
800
]
],
[
[
1064,
25,
1476
],
[
1476,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutam... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cau... |
DB01142 | DB09083 | 1,264 | 880 | [
"DDInter593",
"DDInter996"
] | Doxepin | Ivabradine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1264,
25,
880
]
],
[
[
1264,
63,
480
],
[
480,
24,
880
]
],
[
[
1264,
24,
659
],
[
659,
24,
880
]
],
[
[
1264,
24,
1476
],
[
1476,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol m... |
DB01059 | DB08882 | 956 | 1,281 | [
"DDInter1313",
"DDInter1070"
] | Norfloxacin | Linagliptin | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
956,
24,
1281
]
],
[
[
956,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
956,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
956,
21,
29081
],
[
29081,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Norfloxacin (Compound) causes Angioedema (Side Effect) and Ang... |
DB00774 | DB00983 | 1,577 | 480 | [
"DDInter889",
"DDInter776"
] | Hydroflumethiazide | Formoterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1577,
24,
480
]
],
[
[
1577,
18,
10375
],
[
10375,
57,
480
]
],
[
[
1577,
21,
28762
],
[
28762,
60,
480
]
],
[
[
1577,
63,
218
],
[
21... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is d... | Hydroflumethiazide (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Formoterol (Compound)
Hydroflumethiazide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Formoterol (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseas... |
DB00501 | DB00939 | 752 | 1,338 | [
"DDInter380",
"DDInter1135"
] | Cimetidine | Meclofenamic acid | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Minor | 0 | [
[
[
752,
23,
1338
]
],
[
[
752,
6,
10612
],
[
10612,
45,
1338
]
],
[
[
752,
21,
28852
],
[
28852,
60,
1338
]
],
[
[
752,
24,
959
],
[
959,... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Comp... | Cimetidine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Meclofenamic acid (Compound)
Cimetidine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Meclofenamic acid (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with G... |
DB00938 | DB06402 | 455 | 1,079 | [
"DDInter1635",
"DDInter1756"
] | Salmeterol | Telavancin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
455,
24,
1079
]
],
[
[
455,
21,
28750
],
[
28750,
60,
1079
]
],
[
[
455,
63,
1181
],
[
1181,
24,
1079
]
],
[
[
455,
24,
124
],
[
124,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u}... | Salmeterol (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Telavancin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases... |
DB00099 | DB00480 | 440 | 1,668 | [
"DDInter735",
"DDInter1035"
] | Filgrastim | Lenalidomide | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Moderate | 1 | [
[
[
440,
24,
1668
]
],
[
[
440,
24,
770
],
[
770,
40,
1668
]
],
[
[
440,
63,
599
],
[
599,
24,
1668
]
],
[
[
440,
24,
384
],
[
384,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that... |
DB01066 | DB08938 | 1,462 | 1,384 | [
"DDInter316",
"DDInter1112"
] | Cefditoren | Magaldrate | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1462,
24,
1384
]
],
[
[
1462,
63,
752
],
[
752,
23,
1384
]
],
[
[
1462,
1,
665
],
[
665,
24,
1384
]
],
[
[
1462,
40,
1145
],
[
1145,
... | [
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Cefditoren (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could e... |
DB04835 | DB11718 | 1,655 | 927 | [
"DDInter1125",
"DDInter640"
] | Maraviroc | Encorafenib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1655,
24,
927
]
],
[
[
1655,
63,
372
],
[
372,
24,
927
]
],
[
[
1655,
24,
1491
],
[
1491,
24,
927
]
],
[
[
1655,
25,
1510
],
[
1510,
... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB04868 | DB06636 | 478 | 1,623 | [
"DDInter1293",
"DDInter980"
] | Nilotinib | Isavuconazonium | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
478,
24,
1623
]
],
[
[
478,
23,
466
],
[
466,
62,
1623
]
],
[
[
478,
63,
222
],
[
222,
23,
1623
]
],
[
[
478,
74,
1419
],
[
1419,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Si... |
DB09101 | DB09280 | 70 | 1,604 | [
"DDInter633",
"DDInter1101"
] | Elvitegravir | Lumacaftor | Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome ... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
70,
25,
1604
]
],
[
[
70,
24,
1017
],
[
1017,
64,
1604
]
],
[
[
70,
63,
868
],
[
868,
25,
1604
]
],
[
[
70,
24,
1017
],
[
1017,
... | [
[
[
"Elvitegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Elvitegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlat... | Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Lumacaftor
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may ... |
DB00180 | DB01263 | 1,351 | 859 | [
"DDInter749",
"DDInter1494"
] | Flunisolide | Posaconazole | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1351,
24,
859
]
],
[
[
1351,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1351,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1351,
24,
384
],
[
384,
... | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Flunisolide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Flunisolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Flunisolide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and... |
DB00367 | DB09043 | 566 | 135 | [
"DDInter1061",
"DDInter36"
] | Levonorgestrel | Albiglutide | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
566,
24,
135
]
],
[
[
566,
63,
1647
],
[
1647,
23,
135
]
],
[
[
566,
63,
176
],
[
176,
24,
135
]
],
[
[
566,
24,
629
],
[
629,
2... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine a... |
DB00414 | DB01181 | 590 | 1,532 | [
"DDInter16",
"DDInter906"
] | Acetohexamide | Ifosfamide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
590,
24,
1532
]
],
[
[
590,
25,
1299
],
[
1299,
23,
1532
]
],
[
[
590,
64,
1176
],
[
1176,
23,
1532
]
],
[
[
590,
25,
255
],
[
255,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
],
[
"T... | Acetohexamide may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Acetohexamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a... |
DB11837 | DB11853 | 1,297 | 230 | [
"DDInter1351",
"DDInter1577"
] | Osilodrostat | Relugolix | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1297,
24,
230
]
],
[
[
1297,
64,
129
],
[
129,
23,
230
]
],
[
[
1297,
63,
1094
],
[
1094,
23,
230
]
],
[
[
1297,
62,
112
],
[
112,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzal... | Osilodrostat may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may... |
DB00250 | DB01087 | 10 | 1,520 | [
"DDInter475",
"DDInter1520"
] | Dapsone | Primaquine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
10,
24,
1520
]
],
[
[
10,
24,
1487
],
[
1487,
64,
1520
]
],
[
[
10,
6,
8374
],
[
8374,
45,
1520
]
],
[
[
10,
21,
28722
],
[
28722,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Primaquine (Compound)
Dapsone (Compound) caus... |
DB00549 | DB12141 | 522 | 971 | [
"DDInter1955",
"DDInter817"
] | Zafirlukast | Gilteritinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
522,
24,
971
]
],
[
[
522,
24,
112
],
[
112,
23,
971
]
],
[
[
522,
24,
700
],
[
700,
24,
971
]
],
[
[
522,
24,
242
],
[
242,
63,... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin ... |
DB00697 | DB01001 | 876 | 688 | [
"DDInter1821",
"DDInter1632"
] | Tizanidine | Salbutamol | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
876,
24,
688
]
],
[
[
876,
24,
455
],
[
455,
24,
688
]
],
[
[
876,
24,
1148
],
[
1148,
63,
688
]
],
[
[
876,
21,
28714
],
[
28714,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isop... |
DB00059 | DB06210 | 1,560 | 72 | [
"DDInter1404",
"DDInter631"
] | Pegaspargase | Eltrombopag | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
1560,
24,
72
]
],
[
[
1560,
24,
384
],
[
384,
63,
72
]
],
[
[
1560,
24,
467
],
[
467,
24,
72
]
],
[
[
1560,
63,
268
],
[
268,
25... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and ... |
DB01225 | DB01254 | 500 | 1,213 | [
"DDInter645",
"DDInter484"
] | Enoxaparin | Dasatinib | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
500,
25,
1213
]
],
[
[
500,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
500,
23,
539
],
[
539,
62,
1213
]
],
[
[
500,
24,
738
],
[
738,
... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Enoxaparin",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Si... | Enoxaparin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effect... |
DB00738 | DB05812 | 485 | 1,374 | [
"DDInter1420",
"DDInter8"
] | Pentamidine | Abiraterone | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
485,
24,
1374
]
],
[
[
485,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
485,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
485,
23,
112
],
[
112,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Pentamidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Pentamidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Pentamidine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole an... |
DB00480 | DB06404 | 1,668 | 1,514 | [
"DDInter1035",
"DDInter869"
] | Lenalidomide | Human C1-esterase inhibitor | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | Major | 2 | [
[
[
1668,
25,
1514
]
],
[
[
1668,
25,
1423
],
[
1423,
24,
1514
]
],
[
[
1668,
25,
1126
],
[
1126,
63,
1514
]
],
[
[
1668,
64,
380
],
[
380... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ospemifene"
],
[
"Ospe... | Lenalidomide may lead to a major life threatening interaction when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Lenalidomide may lead to a major life threatening interaction when taken with Peginesatide and Peginesatide ... |
DB00761 | DB00777 | 1,621 | 146 | [
"DDInter1497",
"DDInter1537"
] | Potassium chloride | Propiomazine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Major | 2 | [
[
[
1621,
25,
146
]
],
[
[
1621,
64,
508
],
[
508,
1,
146
]
],
[
[
1621,
25,
401
],
[
401,
63,
146
]
],
[
[
1621,
25,
1178
],
[
1178,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propiomazine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazin... | Potassium chloride may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbat... |
DB00427 | DB00843 | 1,233 | 479 | [
"DDInter1879",
"DDInter583"
] | Triprolidine | Donepezil | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1233,
24,
479
]
],
[
[
1233,
24,
843
],
[
843,
1,
479
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
479
]
],
[
[
1233,
7,
2900
],
[
2900,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound)
Triprolidine (Compound) upregulates NFKBIA (Gene) and NFKB... |
DB00712 | DB00881 | 1,274 | 954 | [
"DDInter763",
"DDInter1554"
] | Flurbiprofen | Quinapril | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
1274,
24,
954
]
],
[
[
1274,
63,
1638
],
[
1638,
1,
954
]
],
[
[
1274,
24,
664
],
[
664,
1,
954
]
],
[
[
1274,
63,
1523
],
[
1523,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril (Compound) resembles Quinapril (Co... |
DB00372 | DB00381 | 999 | 376 | [
"DDInter1793",
"DDInter79"
] | Thiethylperazine | Amlodipine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Moderate | 1 | [
[
[
999,
24,
376
]
],
[
[
999,
63,
1428
],
[
1428,
1,
376
]
],
[
[
999,
24,
409
],
[
409,
1,
376
]
],
[
[
999,
24,
1081
],
[
1081,
4... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Amlodipine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Amlodipine... |
DB00964 | DB01142 | 1,617 | 1,264 | [
"DDInter110",
"DDInter593"
] | Apraclonidine | Doxepin | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1617,
24,
1264
]
],
[
[
1617,
24,
401
],
[
401,
24,
1264
]
],
[
[
1617,
63,
832
],
[
832,
24,
1264
]
],
[
[
1617,
24,
649
],
[
649,
... | [
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine... |
DB00529 | DB09020 | 789 | 28 | [
"DDInter779",
"DDInter212"
] | Foscarnet | Bisacodyl | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
789,
24,
28
]
],
[
[
789,
21,
28809
],
[
28809,
60,
28
]
],
[
[
789,
24,
823
],
[
823,
63,
28
]
],
[
[
789,
24,
870
],
[
870,
24... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused ... | Foscarnet (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB06081 | DB10344 | 1,046 | 992 | [
"DDInter286",
"DDInter818"
] | Caplacizumab | Ginger | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1046,
24,
992
]
],
[
[
1046,
64,
1578
],
[
1578,
24,
992
]
],
[
[
1046,
25,
1421
],
[
1421,
63,
992
]
],
[
[
1046,
25,
802
],
[
802,
... | [
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",... | Caplacizumab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Caplacizumab may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate intera... |
DB00400 | DB08932 | 353 | 1,398 | [
"DDInter843",
"DDInter1111"
] | Griseofulvin | Macitentan | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
353,
24,
1398
]
],
[
[
353,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
353,
21,
28762
],
[
28762,
60,
1398
]
],
[
[
353,
24,
1478
],
[
1478,... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Griseofulvin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Macitentan (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and I... |
DB06176 | DB14783 | 1,342 | 287 | [
"DDInter1616",
"DDInter574"
] | Romidepsin | Diroximel fumarate | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1342,
24,
287
]
],
[
[
1342,
24,
384
],
[
384,
24,
287
]
],
[
[
1342,
63,
599
],
[
599,
24,
287
]
],
[
[
1342,
64,
478
],
[
478,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab a... |
DB01082 | DB05351 | 1,448 | 101 | [
"DDInter1713",
"DDInter519"
] | Streptomycin | Dexlansoprazole | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
1448,
24,
101
]
],
[
[
1448,
63,
1479
],
[
1479,
23,
101
]
],
[
[
1448,
24,
972
],
[
972,
62,
101
]
],
[
[
1448,
63,
589
],
[
589,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ac... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken... |
DB01088 | DB15233 | 714 | 1,650 | [
"DDInter908",
"DDInter142"
] | Iloprost | Avapritinib | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
714,
25,
1650
]
],
[
[
714,
24,
557
],
[
557,
24,
1650
]
],
[
[
714,
63,
121
],
[
121,
24,
1650
]
],
[
[
714,
63,
1512
],
[
1512,
... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxych... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine... |
DB00683 | DB09330 | 1,382 | 985 | [
"DDInter1212",
"DDInter1352"
] | Midazolam | Osimertinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1382,
24,
985
]
],
[
[
1382,
63,
608
],
[
608,
23,
985
]
],
[
[
1382,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1382,
24,
283
],
[
283,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor ma... |
DB00712 | DB01067 | 1,274 | 959 | [
"DDInter763",
"DDInter826"
] | Flurbiprofen | Glipizide | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1274,
24,
959
]
],
[
[
1274,
63,
245
],
[
245,
40,
959
]
],
[
[
1274,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1274,
6,
6017
],
[
6017,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00647 | DB06176 | 675 | 1,342 | [
"DDInter528",
"DDInter1616"
] | Dextropropoxyphene | Romidepsin | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
675,
24,
1342
]
],
[
[
675,
23,
112
],
[
112,
23,
1342
]
],
[
[
675,
24,
485
],
[
485,
24,
1342
]
],
[
[
675,
24,
1616
],
[
1616,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Pen... |
DB00640 | DB01268 | 1,585 | 1,151 | [
"DDInter31",
"DDInter1731"
] | Adenosine | Sunitinib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1585,
24,
1151
]
],
[
[
1585,
18,
2183
],
[
2183,
57,
1151
]
],
[
[
1585,
21,
28653
],
[
28653,
60,
1151
]
],
[
[
1585,
24,
1250
],
[
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (... | Adenosine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Sunitinib (Compound)
Adenosine (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Sunitinib (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Pazopa... |
DB00477 | DB01105 | 216 | 222 | [
"DDInter363",
"DDInter1665"
] | Chlorpromazine | Sibutramine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
216,
24,
222
]
],
[
[
216,
6,
8374
],
[
8374,
45,
222
]
],
[
[
216,
18,
9385
],
[
9385,
57,
222
]
],
[
[
216,
7,
8386
],
[
8386,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Chlorpromazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Chlorpromazine (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound)
Chlorpromazine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Sibutramine (Com... |
DB01132 | DB08870 | 1,130 | 850 | [
"DDInter1472",
"DDInter228"
] | Pioglitazone | Brentuximab vedotin | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1130,
24,
850
]
],
[
[
1130,
63,
267
],
[
267,
24,
850
]
],
[
[
1130,
24,
1033
],
[
1033,
63,
850
]
],
[
[
1130,
24,
651
],
[
651,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisi... |
DB00377 | DB00581 | 1,494 | 355 | [
"DDInter1382",
"DDInter1018"
] | Palonosetron | Lactulose | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
1494,
24,
355
]
],
[
[
1494,
21,
29180
],
[
29180,
60,
355
]
],
[
[
1494,
24,
286
],
[
286,
62,
355
]
],
[
[
1494,
24,
1262
],
[
1262,... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"... | Palonosetron (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Lactulose (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit... |
DB00400 | DB12887 | 353 | 1,598 | [
"DDInter843",
"DDInter1750"
] | Griseofulvin | Tazemetostat | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
353,
24,
1598
]
],
[
[
353,
62,
608
],
[
608,
23,
1598
]
],
[
[
353,
24,
594
],
[
594,
24,
1598
]
],
[
[
353,
63,
134
],
[
134,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[... | Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutin... |
DB00741 | DB04855 | 167 | 540 | [
"DDInter885",
"DDInter602"
] | Hydrocortisone | Dronedarone | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
167,
25,
540
]
],
[
[
167,
64,
228
],
[
228,
40,
540
]
],
[
[
167,
25,
33
],
[
33,
40,
540
]
],
[
[
167,
6,
8374
],
[
8374,
45,
... | [
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
... | Hydrocortisone may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Hydrocortisone (Comp... |
DB00196 | DB00615 | 600 | 690 | [
"DDInter743",
"DDInter1589"
] | Fluconazole | Rifabutin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Moderate | 1 | [
[
[
600,
24,
690
]
],
[
[
600,
25,
463
],
[
463,
1,
690
]
],
[
[
600,
6,
8374
],
[
8374,
45,
690
]
],
[
[
600,
21,
29062
],
[
29062,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampici... | Fluconazole may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Fluconazole (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Eff... |
DB06603 | DB06788 | 39 | 1,616 | [
"DDInter1387",
"DDInter864"
] | Panobinostat | Histrelin | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
39,
25,
1616
]
],
[
[
39,
62,
112
],
[
112,
23,
1616
]
],
[
[
39,
64,
1664
],
[
1664,
24,
1616
]
],
[
[
39,
24,
603
],
[
603,
63... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Panobinostat may lead to a major life threatening interaction when taken with Risperidone and Risperidone may... |
DB05578 | DB06081 | 330 | 1,046 | [
"DDInter1566",
"DDInter286"
] | Ramucirumab | Caplacizumab | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
330,
25,
1046
]
],
[
[
330,
63,
1039
],
[
1039,
24,
1046
]
],
[
[
330,
64,
1171
],
[
1171,
24,
1046
]
],
[
[
330,
24,
1427
],
[
1427,
... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"D... | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Ramucirumab may lead to a major life threatening interaction when taken with Meloxicam and Meloxica... |
DB00705 | DB09074 | 441 | 1,362 | [
"DDInter496",
"DDInter1327"
] | Delavirdine | Olaparib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
441,
25,
1362
]
],
[
[
441,
23,
896
],
[
896,
24,
1362
]
],
[
[
441,
24,
2
],
[
2,
24,
1362
]
],
[
[
441,
25,
1478
],
[
1478,
24... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
],
[
"Etoposide",
... | Delavirdine may cause a minor interaction that can limit clinical effects when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron m... |
DB00153 | DB00252 | 1,331 | 362 | [
"DDInter662",
"DDInter1460"
] | Ergocalciferol | Phenytoin | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Moderate | 1 | [
[
[
1331,
24,
362
]
],
[
[
1331,
24,
759
],
[
759,
40,
362
]
],
[
[
1331,
6,
8374
],
[
8374,
45,
362
]
],
[
[
1331,
21,
29024
],
[
29024,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenytoin (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Phenytoin (Compound)
Ergocalciferol (Compound) causes Hypertension (Side Effect) an... |
DB01211 | DB08868 | 609 | 1,011 | [
"DDInter393",
"DDInter737"
] | Clarithromycin | Fingolimod | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
609,
25,
1011
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
609,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
609,
62,
1247
],
[
1247,... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Clarithromycin (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with... |
DB00780 | DB06691 | 551 | 849 | [
"DDInter1440",
"DDInter1155"
] | Phenelzine | Mepyramine | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
551,
24,
849
]
],
[
[
551,
64,
1594
],
[
1594,
24,
849
]
],
[
[
551,
24,
272
],
[
272,
24,
849
]
],
[
[
551,
63,
128
],
[
128,
2... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Phenelzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxylamine"
],
[
"Doxylamine... | Phenelzine may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramin... |
DB00247 | DB11901 | 1,131 | 913 | [
"DDInter1194",
"DDInter107"
] | Methysergide | Apalutamide | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1131,
24,
913
]
],
[
[
1131,
63,
600
],
[
600,
24,
913
]
],
[
[
1131,
25,
609
],
[
609,
24,
913
]
],
[
[
1131,
40,
588
],
[
588,
... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Methysergide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithrom... |
DB00618 | DB11110 | 1,572 | 603 | [
"DDInter498",
"DDInter1115"
] | Demeclocycline | Magnesium citrate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1572,
24,
603
]
],
[
[
1572,
62,
863
],
[
863,
24,
603
]
],
[
[
1572,
23,
1326
],
[
1326,
24,
603
]
],
[
[
1572,
1,
1545
],
[
1545,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
... | Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Diclofenamid... |
DB00748 | DB01080 | 662 | 855 | [
"DDInter297",
"DDInter1933"
] | Carbinoxamine | Vigabatrin | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Moderate | 1 | [
[
[
662,
24,
855
]
],
[
[
662,
21,
28975
],
[
28975,
60,
855
]
],
[
[
662,
24,
407
],
[
407,
63,
855
]
],
[
[
662,
24,
401
],
[
401,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is ca... | Carbinoxamine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Vigabatrin (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Carb... |
DB08901 | DB11967 | 1,468 | 710 | [
"DDInter1492",
"DDInter210"
] | Ponatinib | Binimetinib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Major | 2 | [
[
[
1468,
25,
710
]
],
[
[
1468,
64,
441
],
[
441,
24,
710
]
],
[
[
1468,
63,
1593
],
[
1593,
24,
710
]
],
[
[
1468,
25,
68
],
[
68,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} ... | Ponatinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause... |
DB00559 | DB06589 | 152 | 1,250 | [
"DDInter223",
"DDInter1400"
] | Bosentan | Pazopanib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
152,
24,
1250
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
152,
18,
5795
],
[
5795,
46,
1250
]
],
[
[
152,
21,
28868
],
[
28868,... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Bosentan (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is upregulated by Pazopanib (Compound)
Bosentan (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopanib (Compound)
Bosentan ma... |
DB00352 | DB00814 | 482 | 1,171 | [
"DDInter1814",
"DDInter1143"
] | Tioguanine | Meloxicam | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
482,
24,
1171
]
],
[
[
482,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
482,
6,
9320
],
[
9320,
45,
1171
]
],
[
[
482,
21,
28826
],
[
28826,... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Tioguanine (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Meloxicam (Compound)
Tioguanine (Compound) causes Jaundice (Side Effect) and Jaundice (Side E... |
DB04868 | DB08904 | 478 | 375 | [
"DDInter1293",
"DDInter342"
] | Nilotinib | Certolizumab pegol | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
478,
25,
375
]
],
[
[
478,
64,
704
],
[
704,
24,
375
]
],
[
[
478,
24,
200
],
[
200,
63,
375
]
],
[
[
478,
63,
143
],
[
143,
24,... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u}... | Nilotinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albic... |
DB00078 | DB11601 | 1,172 | 1,270 | [
"DDInter898",
"DDInter1889"
] | Ibritumomab tiuxetan | Tuberculin purified protein derivative | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1172,
24,
1270
]
],
[
[
1172,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1172,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
1172,
25,
1259
],
[
12... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when tak... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Ibritumomab tiuxetan may lead to a major life threatening interaction wh... |
DB00615 | DB11986 | 690 | 484 | [
"DDInter1589",
"DDInter648"
] | Rifabutin | Entrectinib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
690,
25,
484
]
],
[
[
690,
24,
112
],
[
112,
23,
484
]
],
[
[
690,
24,
466
],
[
466,
62,
484
]
],
[
[
690,
24,
1662
],
[
1662,
2... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and D... |
DB08899 | DB09038 | 129 | 1,450 | [
"DDInter649",
"DDInter636"
] | Enzalutamide | Empagliflozin | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
129,
24,
1450
]
],
[
[
129,
63,
485
],
[
485,
24,
1450
]
],
[
[
129,
24,
659
],
[
659,
63,
1450
]
],
[
[
129,
64,
165
],
[
165,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol a... |
DB00439 | DB06772 | 289 | 310 | [
"DDInter341",
"DDInter259"
] | Cerivastatin | Cabazitaxel | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
289,
24,
310
]
],
[
[
289,
24,
973
],
[
973,
24,
310
]
],
[
[
289,
24,
868
],
[
868,
63,
310
]
],
[
[
289,
63,
10
],
[
10,
24,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and ... |
DB00011 | DB00059 | 1,451 | 1,560 | [
"DDInter944",
"DDInter1404"
] | Interferon alfa-n1 | Pegaspargase | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moderate | 1 | [
[
[
1451,
24,
1560
]
],
[
[
1451,
24,
372
],
[
372,
63,
1560
]
],
[
[
1451,
24,
1257
],
[
1257,
24,
1560
]
],
[
[
1451,
25,
72
],
[
72,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabi... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB00635 | DB00976 | 1,573 | 1,056 | [
"DDInter1515",
"DDInter1758"
] | Prednisone | Telithromycin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
1573,
24,
1056
]
],
[
[
1573,
6,
8374
],
[
8374,
45,
1056
]
],
[
[
1573,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
1573,
1,
1220
],
[
12... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Prednisone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a mod... |
DB00564 | DB11967 | 1,236 | 710 | [
"DDInter293",
"DDInter210"
] | Carbamazepine | Binimetinib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1236,
24,
710
]
],
[
[
1236,
25,
1593
],
[
1593,
24,
710
]
],
[
[
1236,
63,
883
],
[
883,
24,
710
]
],
[
[
1236,
24,
1619
],
[
1619,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Cri... | Carbamazepine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may c... |
DB00564 | DB00860 | 1,236 | 891 | [
"DDInter293",
"DDInter1513"
] | Carbamazepine | Prednisolone | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1236,
24,
891
]
],
[
[
1236,
24,
175
],
[
175,
40,
891
]
],
[
[
1236,
24,
1547
],
[
1547,
1,
891
]
],
[
[
1236,
63,
251
],
[
251,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane (Compound) resembles Predniso... |
DB00022 | DB01073 | 268 | 1,488 | [
"DDInter1408",
"DDInter745"
] | Peginterferon alfa-2b | Fludarabine | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
268,
24,
1488
]
],
[
[
268,
24,
372
],
[
372,
1,
1488
]
],
[
[
268,
24,
1253
],
[
1253,
24,
1488
]
],
[
[
268,
24,
36
],
[
36,
6... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clof... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a modera... |
DB00622 | DB08907 | 1,081 | 1,344 | [
"DDInter1287",
"DDInter280"
] | Nicardipine | Canagliflozin | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1081,
24,
1344
]
],
[
[
1081,
24,
549
],
[
549,
1,
1344
]
],
[
[
1081,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
1081,
21,
28681
],
[
28681... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nicardipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Nicardipine (Compound) causes Hypersensitivity (Side E... |
DB00262 | DB10989 | 552 | 496 | [
"DDInter302",
"DDInter858"
] | Carmustine | Hepatitis A Vaccine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
552,
24,
496
]
],
[
[
552,
24,
4
],
[
4,
24,
496
]
],
[
[
552,
24,
738
],
[
738,
63,
496
]
],
[
[
552,
25,
976
],
[
976,
24,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Carmustine may cause a moderate interaction that could exacerbate disease... |
DB01182 | DB08904 | 371 | 375 | [
"DDInter1534",
"DDInter342"
] | Propafenone | Certolizumab pegol | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
371,
24,
375
]
],
[
[
371,
40,
704
],
[
704,
24,
375
]
],
[
[
371,
25,
1593
],
[
1593,
24,
375
]
],
[
[
371,
62,
608
],
[
608,
2... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a m... | Propafenone (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Propafenone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerba... |
DB01041 | DB01215 | 770 | 1,418 | [
"DDInter1789",
"DDInter677"
] | Thalidomide | Estazolam | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
770,
24,
1418
]
],
[
[
770,
63,
523
],
[
523,
1,
1418
]
],
[
[
770,
63,
1216
],
[
1216,
40,
1418
]
],
[
[
770,
24,
481
],
[
481,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound)
... |
DB00427 | DB09293 | 1,233 | 116 | [
"DDInter1879",
"DDInter954"
] | Triprolidine | Iodide I-131 | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1233,
24,
116
]
],
[
[
1233,
63,
701
],
[
701,
24,
116
]
],
[
[
1233,
24,
252
],
[
252,
24,
116
]
],
[
[
1233,
24,
337
],
[
337,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and... |
DB05812 | DB08880 | 1,374 | 1,510 | [
"DDInter8",
"DDInter1771"
] | Abiraterone | Teriflunomide | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1374,
25,
1510
]
],
[
[
1374,
25,
129
],
[
129,
63,
1510
]
],
[
[
1374,
24,
1612
],
[
1612,
63,
1510
]
],
[
[
1374,
64,
697
],
[
697,
... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Abiraterone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir... |
DB04865 | DB08904 | 4 | 375 | [
"DDInter1335",
"DDInter342"
] | Omacetaxine mepesuccinate | Certolizumab pegol | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
4,
25,
375
]
],
[
[
4,
25,
1047
],
[
1047,
24,
375
]
],
[
[
4,
24,
200
],
[
200,
63,
375
]
],
[
[
4,
63,
1554
],
[
1554,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansi... | Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate d... |
DB06605 | DB14575 | 1,409 | 733 | [
"DDInter108",
"DDInter674"
] | Apixaban | Eslicarbazepine | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1409,
24,
733
]
],
[
[
1409,
63,
1101
],
[
1101,
23,
733
]
],
[
[
1409,
63,
222
],
[
222,
24,
733
]
],
[
[
1409,
24,
351
],
[
351,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutr... |
DB01083 | DB04938 | 1,142 | 1,423 | [
"DDInter1348",
"DDInter1353"
] | Orlistat | Ospemifene | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Moderate | 1 | [
[
[
1142,
24,
1423
]
],
[
[
1142,
6,
8374
],
[
8374,
45,
1423
]
],
[
[
1142,
21,
28883
],
[
28883,
60,
1423
]
],
[
[
1142,
24,
549
],
[
54... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Orlistat",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Orlistat (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ospemifene (Compound)
Orlistat (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ospemifene (Compound)
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.